PEDEVCO CORP. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by PEDEVCO CORP. (PED) on January 15, 2020, covering events that occurred on January 13, 2020. The filing reports on the annual compensation review and the subsequent issuance of equity awards to officers and employees under the Company's Amended and Restated 2012 Equity Incentive Plan.
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation grants.
Material Changes and Equity Grants
On January 13, 2020, the Board of Directors approved the issuance of the following equity awards:
- Total Restricted Stock: 1,049,000 shares issued to various officers and employees.
- Total Stock Options: Options to purchase 733,000 shares issued to employees.
- Exercise Price: Options were granted with an exercise price of $1.68 per share.
- Vesting Schedule: All awards are subject to "Three Year Vesting Terms," vesting in equal installments (1/3) on the one, two, and three-year anniversaries of the grant date, contingent upon continued service.
Specific Recipients and Allocations:
- Dr. Simon G. Kukes (CEO): 510,000 restricted shares.
- Mr. J. Douglas Schick (President): 162,000 restricted shares.
- Mr. Clark R. Moore (EVP, General Counsel, Secretary): 162,000 restricted shares.
- Mr. Paul Pinkston (Chief Accounting Officer): 90,000 restricted shares.
- Other Non-Executive Employees: 125,000 restricted shares and options to purchase 718,000 shares.
- Dr. Simon G. Kukes' Wife (Employee): Options to purchase 15,000 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, outlook, or specific risks. The primary contingency noted is that all equity awards are subject to the recipients' continued service to the Company on the respective vesting dates.
Key Facts for Investor Verification
- Verify the total number of shares authorized under the 2012 Equity Incentive Plan to assess remaining capacity for future grants.
- Confirm the current market price of PED stock relative to the $1.68 option exercise price to evaluate the intrinsic value of the grants.
- Review the Company's most recent 10-K or 10-Q for financial context, as this 8-K contains no financial performance data.
- Note that the grants represent a significant portion of the company's equity compensation strategy for the year, heavily weighted toward executive leadership.